Quarterly report pursuant to Section 13 or 15(d)

Document and Entity Information

v3.8.0.1
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2016
Nov. 14, 2016
Document And Entity Information    
Entity Registrant Name GT Biopharma, Inc.  
Entity Central Index Key 0000109657  
Document Type 10-Q/A  
Document Period End Date Sep. 30, 2016  
Amendment Flag true  
Amendment Description

GT Biopharma, Inc., formerly known as Oxis International, Inc, (the “Company”) is filing this Amendment No. 1 to its Quarterly Report on Form 10-Q for its nine months ended September 30, 2016, as filed with the Securities and Exchange Commission on November 14, 2016 (the “Original September 2016 Form 10-Q”), primarily to correct an error related to the non-cash calculation of warranty liabilities.

 

Actual Changes in the Original September 2016 Form 10-Q. The actual changes in the Original September 2016 Form 10-Q included in this Amendment No. 1 are amendments to: (a) amended and restated Consolidated Statement of Operations for the nine months ended September 30, 2016, (b) amended and restated Consolidated Statement of Cash Flows for the nine months ended September 30, 2016, and (c) the addition of Note 7.

 

Notwithstanding that there are no changes in most of the Notes to the Consolidated Financial Statements included in this Amendment No. 1, a complete Form 10-Q document including a complete set of the Consolidated Financial Statements (together with all of the Notes from the Original September 2016 10-Q) has been included in this Amendment No. 1, for convenient reference.

 

In addition, see additional amended filings of the Company for relevant subsequent events.

 
Current Fiscal Year End Date --12-31  
Is Entity a Well-known Seasoned Issuer? No  
Is Entity a Voluntary Filer? No  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   30,241,305
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2016